Akebia Therapeutics Inc.

NASDAQ: AKBA · Real-Time Price · USD
3.24
-0.05 (-1.52%)
At close: Aug 15, 2025, 3:59 PM
3.22
-0.62%
After-hours: Aug 15, 2025, 06:10 PM EDT

Akebia Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
160.18M 194.62M 292.6M 213.58M
Cost of Revenue
63.18M 74.15M 84.8M 153.39M
Gross Profit
97M 120.47M 207.81M 60.18M
Operating Income
-50.47M -46.26M -63.18M -265.32M
Interest Income
n/a n/a n/a n/a
Pretax Income
-69.41M -51.92M -92.56M -282.84M
Net Income
-69.41M -51.92M -106.01M -244.87M
Selling & General & Admin
106.55M 100.23M 138.6M 174.14M
Research & Development
37.65M 63.08M 129.11M 147.85M
Other Expenses
3.28M 3.42M -12.54M 3.49M
Operating Expenses
147.47M 166.73M 270.99M 325.5M
Interest Expense
18.18M 6.03M 15.69M 19.94M
Selling & Marketing Expenses
n/a 100.23M 6.7M 8.2M
Cost & Expenses
171.33M 240.88M 355.78M 478.9M
Income Tax Expense
n/a n/a 13.45M -37.97M
Shares Outstanding (Basic)
210.95M 187.47M 182.78M 165.95M
Shares Outstanding (Diluted)
210.95M 187.47M 182.78M 165.95M
EPS (Basic)
-0.33 -0.28 -0.58 -1.48
EPS (Diluted)
-0.33 -0.28 -0.58 -1.48
EBITDA
-13.72M -6.87M -43.26M -225.96M
EBIT
-51.23M -45.89M -78.54M -262.09M
Depreciation & Amortization
36.75M 37.63M 35.28M 36.13M